» Articles » PMID: 4004819

Myoadenylate Deaminase Deficiency: Inherited and Acquired Forms

Overview
Journal Biochem Med
Specialty Biochemistry
Date 1985 Apr 1
PMID 4004819
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Myoadenylate deaminase deficiency, the most common of the known enzyme deficits of muscle, appears to occur in two forms. The primary type seems to be inherited as a complete gene block in an autosomal recessive pattern. Although occasionally diagnosed in infancy, when muscle biopsy is performed on a hypotonic but normoreflexic child, the deficiency is usually not symptomatic until adult or middle age, when muscle cramping and exercise intolerance develop. The skeletal muscle isozyme is immunologically, and presumably genetically, unique, and these patients have normal levels of adenylate deaminase in their other cells and tissues. A presumptive diagnosis can usually be made by an ischemic forearm exercise test, which shows a negligible increase in blood ammonia, despite a normal rise in lactate. Despite the absence of more than 99% of normal adenylate deaminase activity, the muscle biopsy shows no anatomic pathology, and other enzymes are at normal levels. These patients do not suffer progressive disease, and should be reassured, and encouraged to maintain physical activity. The heterozygous state is probably asymptomatic, except, perhaps, on extreme exercise, but may be associated with an increased incidence of malignant hyperthermia susceptibility. Since the gene defect is not rare, it is not surprising that some cases of the deficiency will be coincidentally associated with other neuromuscular disease. However, there is also a secondary form of myoadenylate deaminase deficiency, consequent to muscle damage from other disease. In this form, the residual activity is higher (1-10% of normal), may present rare foci of positive stain in the section, and reacts normally with antibody to the muscle isozyme. Other muscle enzymes are also depleted, although not as severely, and the prognosis in such cases is dictated by the primary disease. Since the heterozygous state is common, these patients might have been carriers, whose adenylate deaminase levels have been lowered for the deficient category by the advent of other neuromuscular disease.

Citing Articles

A window into intracellular events in myositis through subcellular proteomics.

Peterson J, Leclair V, Oyebode O, Herzallah D, Nestor-Kalinoski A, Morais J Inflamm Res. 2025; 74(1):31.

PMID: 39890639 PMC: 11785624. DOI: 10.1007/s00011-025-01996-8.


Integrated Functions of Cardiac Energetics, Mechanics, and Purine Nucleotide Metabolism.

Lopez-Schenk R, Collins N, Schenk N, Beard D Compr Physiol. 2023; 14(1):5345-5369.

PMID: 38158366 PMC: 10956446. DOI: 10.1002/cphy.c230011.


Two Rare Cases of Long Surviving Riboflavin Transporter Deficiency with Co-Existing Adenosine Monophosphate Deaminase (AMP) Deficiency.

Zhang L, Thyagarajan D Brain Sci. 2022; 12(12).

PMID: 36552065 PMC: 9775375. DOI: 10.3390/brainsci12121605.


Secondary myoadenylate deaminase deficiency is not a common feature of inflammatory myopathies: A descriptive study.

Wilkinson M, Cash K, Gutschmidt B, Otto S, Limaye V Front Med (Lausanne). 2022; 9:1061722.

PMID: 36507531 PMC: 9727292. DOI: 10.3389/fmed.2022.1061722.


Improved skeletal muscle fatigue resistance in experimental autoimmune myositis mice following high-intensity interval training.

Yamada T, Ashida Y, Tamai K, Kimura I, Yamauchi N, Naito A Arthritis Res Ther. 2022; 24(1):156.

PMID: 35761371 PMC: 9235155. DOI: 10.1186/s13075-022-02846-2.